The Genetics of Alzheimer Disease
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Family history is the second strongest risk factor for Alzheimer disease (AD) following advanced age.Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases.The inheritance of AD exhibits a dichotomous pattern.On one hand, rare mutations in APP, PSEN1, and PSEN2 virtually guarantee early-onset (,60 years) familial AD, which represents 5% of AD.On the other hand, common gene polymorphisms, such as the 14 and 12 variants of the APOE gene, can influence susceptibility for 50% of the common late-onset AD.These four genes account for 30% -50% of the inheritability of AD.Genome-wide association studies have recently led to the identification of 11 additional AD candidate genes.This paper reviews the past, present, and future attempts to elucidate the complex and heterogeneous genetic underpinnings of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, 228 PSEN1 mutations have been identified causing ADAD (49, 303, 304, 440, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“CLU gene encodes clusterin or APOJ that besides its functions in lipid transport, membrane recycling, cell adhesion, and apoptosis (90, 444, 600, 677) affects transvascular A 𝛃 clearance by promoting A 𝛃 42 efflux across the BBB (580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PSEN1 mutations lead to faster soluble-to-fibrillar conversion of A 𝛃 42 promoting amyloid deposition in the brain (303, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the major genetic risk factor for sporadic, late-onset AD (199, 368, 580, 612).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [580]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 3×
“Goate et al. (1991), then resequenced the same two APP exons to reveal the first EO-FAD mutation (London mutation; V717I) in APP.”
BackgroundThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“In 1987, we as well as others isolated the amyloid b (A4) protein precursor (APP; Goldgaber et al. 1987; Kang et al. 1987; Tanzi et al. 1987a, 1988) and mapped it to chromosome 21.”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 3×
“1987b); they were ultimately demonstrated to carry PSEN1 mutations (Sherrington et al. 1995).”
BackgroundSelf-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 14×
“Genetic association studies remain the most common method for identifying novel LOAD genes and are most often employed in the form of large-scale GWASs that screen the entire human genome for novel disease loci.”
InfluentialScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 3×
“Whether EO-FAD mutations appear in APP near the g-secretase cleavage site or in the presenilins, the vast majority of them serve to increase the ratio of Ab42:Ab40. g-Secretase modulators are aimed at reversing this ratio and represent very promising compounds for treating and preventing AD based on what has been garn…”
BackgroundSelf-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“Shortly thereafter, we first reported a homolog of PSEN1 called presenilin (PSEN2; Levy-Lahad et al. 1995) on chromosome 1 and showed that it harbors the N141I mutation in Volga-German EO-FAD families.”
BackgroundSelf-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Research works printed but not linked: 2
- Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zis- mann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huen- telman MJ, et al. 2007. Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE 14 car- riers. Neuron 54: 713 -720.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipopro- tein E: High-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90: 1977-1981.
Cited by
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
“Over 200 mutations involving this complex have been observed [34].”
BackgroundHallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
“3,9 A close relationship between lipid metabolism and microglial activation is emerging as lipid related genes are upregulated in the transition from homeostatic to damage-associated microglia.”
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Epidemiology of Alzheimer Disease
Mayeux, R., & Stern, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006239 · Cited by 1,064
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
“Links between Aβ and tau pathogenesis Unlike mutations in APP and PS1/2 that affect Aβ generation in early onset familial AD [285, 286], mutations in MAPT have not been associated with AD [287, 288], suggesting that tau pathogenesis may occur downstream of Aβ accumulation [289].”
BackgroundYeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840
“The origin of nonfamilial AD is less well understood and may depend on a combination of genetic and nongenetic risk factors (Tanzi, 2012).”
BackgroundThe case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768
Plasma Proteome Profiling to Assess Human Health and Disease
Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., & Mann, M. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.015 · Cited by 734
“The apolipoprotein allele APOE4 in the homozygous form is the largest known risk factor for late-onset Alzheimer’s diseasewith a 10-fold higher risk compared with the homozygous APOE3 form (Tanzi, 2012).”
BackgroundAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
“BBB breakdown in PSEN1 transgenic models PSEN1 ADAD mutations lead to elevated Aβ production (Tanzi, 2012; Potter et al., 2013; Karch et al., 2014; Elbert et al., 2015), neuronal dysfunction (Lee et al., 2010; Karch and Goate, 2015), and major cerebrovascular pathology, including BBB breakdown;…”
BackgroundTargeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, R., & Vassar, R. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 630
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Mitochondrial oxidative stress in aging and healthspan
Dai, D.-F., Chiao, Y. A., Marcinek, D. J., Szeto, H. H., & Rabinovitch, P. S. (2014) · Longevity & Healthspan · doi:10.1186/2046-2395-3-6 · Cited by 484
scGNN is a novel graph neural network framework for single-cell RNA-Seq analyses
Wang, J., Ma, A., Chang, Y., Gong, J., Jiang, Y., Qi, R., Wang, C., Fu, H., Ma, Q., & Xu, D. (2021) · Nature Communications · doi:10.1038/s41467-021-22197-x · Cited by 457
Alteration of the microRNA network during the progression of Alzheimer's disease
Lau, P., Bossers, K., Janky, R., Salta, E., Frigerio, C. S., Barbash, S., Rothman, R., Sierksma, A. S. R., Thathiah, A., Greenberg, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201974 · Cited by 474
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
TREM2 variants: new keys to decipher Alzheimer disease pathogenesis
Colonna, M., & Wang, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.7 · Cited by 418
Sex and the development of Alzheimer's disease
Pike, C. J. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23827 · Cited by 402
Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., Winkler, E. A., Ramanathan, A., Kanekiyo, T., Bu, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4025 · Cited by 410
“The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP–3 clathrin assembly protein family.”
BackgroundThe epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
“This hypothesis is applicable especially to early onset familial types of AD (fAD), which have a Page 25 of 111 Ac ce pt ed M an us cr ip t much more evident genetic component than the far more common late onset sporadic AD (sAD) (Tanzi, 2012).”
BackgroundTREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease
Griciuc, A., Patel, S., Federico, A. N., Choi, S. H., Innes, B. J., Oram, M. K., Cereghetti, G., McGinty, D., Anselmo, A., Sadreyev, R. I., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.06.010 · Cited by 378
“Introduction Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia among the elderly (Tanzi, 2012).”
Self-citationSalminen, A., Kaarniranta, K., Kauppinen, A., Ojala, J., Haapasalo, A., Soininen, H., & Hiltunen, M. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.002 · Cited by 364
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
Fu, A. K. Y., Hung, K.-W., Yuen, M. Y. F., Zhou, X., Mak, D. S. Y., Chan, I. C. W., Cheung, T. H., Zhang, B., Fu, W.-Y., Liew, F. Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604032113 · Cited by 369
New Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 344
Microglia-Mediated Synapse Loss in Alzheimer's Disease
Rajendran, L., & Paolicelli, R. C. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1136-17.2017 · Cited by 355
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
“…(APP, MAPT [Tau], SNCA [a-synuclein]), in the genes processing APP into Ab (PSEN1, PSEN2), or in other Immunity 50, April 16, 2019 957 genes such as GRN and C9ORF72 (for review, see [Billingsley et al., 2018; Hinz and Geschwind, 2017; Orme et al., 2018; Selkoe and Podlisny, 2002; Tanzi, 2012].”
BackgroundThe amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease
Thal, D. R., Walter, J., Saido, T. C., & Fändrich, M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1375-y · Cited by 319
Genes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
Vassar, R., Kuhn, P., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., & Lichtenthaler, S. F. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12715 · Cited by 311
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Xu, M., Zhang, D., Luo, R., Wu, Y., Zhou, H., Kong, L., Bi, R., & Yao, Y. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.012 · Cited by 296
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
The Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
Hamilton, L. K., Dufresne, M., Joppé, S. E., Petryszyn, S., Aumont, A., Calon, F., Barnabé-Heider, F., Furtos, A., Parent, M., Chaurand, P., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.001 · Cited by 284
Cardiolipin, Mitochondria, and Neurological Disease
Falabella, M., Vernon, H. J., Hanna, M. G., Claypool, S. M., & Pitceathly, R. D. S. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.01.006 · Cited by 282
“Moreover, the abnormal accumulation of misfolded tau protein and amyloid-ß aggregates observed in familial AD (<5% of cases) have been associated with mutations in the amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and 2) [57].”
BackgroundPeriodontal disease associates with higher brain amyloid load in normal elderly
Kamer, A. R., Pirraglia, E., Tsui, W., Rusinek, H., Vallabhajosula, S., Mosconi, L., Yi, L., McHugh, P., Craig, R. G., Svetcov, S., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.038 · Cited by 268
Cerebrovascular Effects of Apolipoprotein E: Implications for Alzheimer Disease
Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2152 · Cited by 263
Models of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-51 · Cited by 256
“Identification of mutations in amyloid precursor protein (APP) and presenilin (PS1/2) that are autosomal dominantly linked to early onset familial AD [6,7], represented major milestones in AD research.”
BackgroundGenetics of familial and sporadic Alzheimer s disease
Piaceri, I. (2013) · Frontiers in Bioscience · doi:10.2741/e605 · Cited by 256
Advances and Utility of the Human Plasma Proteome
Deutsch, E. W., Omenn, G. S., Sun, Z., Maes, M., Pernemalm, M., Palaniappan, K. K., Letunica, N., Vandenbrouck, Y., Brun, V., Tao, S.-C., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00657 · Cited by 246
Alzheimer’s Disease: From Firing Instability to Homeostasis Network Collapse
Frere, S., & Slutsky, I. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.028 · Cited by 237
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242
Molecular and Cellular Basis of Neurodegeneration in Alzheimer’s Disease
Jeong, S. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0096 · Cited by 233
Mullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213
Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
Mendelsohn, A. R., & Larrick, J. W. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1530 · Cited by 209
Alzheimer’s disease as an inflammatory disease
Bolós, M., Perea, J. R., & Avila, J. (2017) · BioMolecular Concepts · doi:10.1515/bmc-2016-0029 · Cited by 216
“In the familial type of AD (FAD), which has an incidence below 5%, mutations in APP and in presenilin 1 and 2 genes can lead to increased levels of Aβ, which may be related to the onset of the disease (4).”
BackgroundAβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level
Sadleir, K. R., Eimer, W. A., Cole, S. L., & Vassar, R. (2015) · Molecular Neurodegeneration · doi:10.1186/1750-1326-10-1 · Cited by 213
Neurosteroids as regulators of neuroinflammation
Yilmaz, C., Karali, K., Fodelianaki, G., Gravanis, A., Chavakis, T., Charalampopoulos, I., & Alexaki, V. I. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100788 · Cited by 213
Ramanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Domingues, C., da Cruz e Silva, O. A. B., & Henriques, A. G. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170317113606 · Cited by 203
The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Wolfe, C. M., Fitz, N. F., Nam, K. N., Lefterov, I., & Koldamova, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010081 · Cited by 187
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
“In a small number of AD patients the onset of dementia is before the age of 60, and they are classified as “early onset familial AD” (EO-FAD) patients; further, they present mutations in APP (amyloid precursor protein gen), PSEN1, and PSEN2 (presenilin genes) [95].”
BackgroundThe role of innate immune genes in Alzheimer's disease
Griciuc, A., & Tanzi, R. E. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000911 · Cited by 192
Self-citationVasconcelos, B., Stancu, I.-C., Buist, A., Bird, M., Wang, P., Vanoosthuyse, A., Van Kolen, K., Verheyen, A., Kienlen-Campard, P., Octave, J.-N., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1525-x · Cited by 192
Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment
van Bergen, J. M. G., Li, X., Hua, J., Schreiner, S. J., Steininger, S. C., Quevenco, F. C., Wyss, M., Gietl, A. F., Treyer, V., Leh, S. E., et al. (2016) · Scientific Reports · doi:10.1038/srep35514 · Cited by 180
Neuronal dark matter: the emerging role of microRNAs in neurodegeneration
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00178 · Cited by 187
The genetics of Alzheimer's disease
Bagyinszky, E., Youn, Y. C., An, S., & Kim, S. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s51571 · Cited by 173
Alzheimer’s Disease and Type 2 Diabetes: Multiple Mechanisms Contribute to Interactions
Jayaraman, A., & Pike, C. J. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0476-2 · Cited by 182
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
“Likewise, genetic variation in the apolipoprotein-E (APOE) gene encoding a lipoprotein involved in the clearance of Aβ is strongly associated with the risk of developing late-onset sporadic AD [27, 28].”
BackgroundScott, J. D., Li, S. W., Brunskill, A. P. J., Chen, X., Cox, K., Cumming, J. N., Forman, M., Gilbert, E. J., Hodgson, R. A., Hyde, L. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00307 · Cited by 174
Selkoe, D., Mandelkow, E., & Holtzman, D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011460 · Cited by 173
Development and Mechanism of γ-Secretase Modulators for Alzheimer’s Disease
Crump, C. J., Johnson, D. S., & Li, Y.-M. (2013) · Biochemistry · doi:10.1021/bi400377p · Cited by 171
Role of Vitamin E in the Treatment of Alzheimer’s Disease: Evidence from Animal Models
Gugliandolo, A., Bramanti, P., & Mazzon, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122504 · Cited by 164
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?
Mayne, K., White, J. A., McMurran, C. E., Rivera, F. J., & de la Fuente, A. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572090 · Cited by 167
“Age is the most important risk factor for AD, with ∼90% of cases being late-onset and ∼10% early-onset (Tanzi, 2012; Bature et al., 2017).”
BackgroundColacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167
ApoE4 upregulates the activity of mitochondria‐associated ER membranes
Tambini, M. D., Pera, M., Kanter, E., Yang, H., Guardia‐Laguarta, C., Holtzman, D., Sulzer, D., Area‐Gomez, E., & Schon, E. A. (2016) · The EMBO Reports · doi:10.15252/embr.201540614 · Cited by 166
Youssef, S. A., Capucchio, M. T., Rofina, J. E., Chambers, J. K., Uchida, K., Nakayama, H., & Head, E. (2016) · Veterinary Pathology · doi:10.1177/0300985815623997 · Cited by 152
The Role of ADAM10 in Alzheimer’s Disease
Yuan, X.-Z., Sun, S., Tan, C.-C., Yu, J.-T., & Tan, L. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170061 · Cited by 160
Wang, Z., Jackson, R. J., Hong, W., Taylor, W. M., Corbett, G. T., Moreno, A., Liu, W., Li, S., Frosch, M. P., Slutsky, I., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2009-17.2017 · Cited by 158
Cellular cholesterol homeostasis and Alzheimer’s disease
Chang, T.-Y., Yamauchi, Y., Hasan, M. T., & Chang, C. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075630 · Cited by 155
“For LOAD, besides aging, the ApoE4 allele is the most important risk factor (126, 127).”
BackgroundCogswell, P. M., Barakos, J. A., Barkhof, F., Benzinger, T. S., Jack, C. R., Poussaint, T. Y., Raji, C. A., Ramanan, V. K., & Whitlow, C. T. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7586 · Cited by 144
Zeineh, M. M., Chen, Y., Kitzler, H. H., Hammond, R., Vogel, H., & Rutt, B. K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.022 · Cited by 151
β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Penke, B., Bogár, F., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22101692 · Cited by 132
A Drosophila model of closed head traumatic brain injury
Katzenberger, R. J., Loewen, C. A., Wassarman, D. R., Petersen, A. J., Ganetzky, B., & Wassarman, D. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316895110 · Cited by 142
Delgado-Morales, R., Agís-Balboa, R. C., Esteller, M., & Berdasco, M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0365-z · Cited by 143
Atherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols, vasculature
Lathe, R., Sapronova, A., & Kotelevtsev, Y. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-36 · Cited by 137
X chromosome aneuploidy in the Alzheimer’s disease brain
Yurov, Y. B., Vorsanova, S. G., Liehr, T., Kolotii, A. D., & Iourov, I. Y. (2014) · Molecular Cytogenetics · doi:10.1186/1755-8166-7-20 · Cited by 140
Blood-brain barrier integrity in the pathogenesis of Alzheimer’s disease
Huang, Z., Wong, L.-W., Su, Y., Huang, X., Wang, N., Chen, H., & Yi, C. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100857 · Cited by 126
The Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease
Czapski, G. A., Czubowicz, K., Strosznajder, J. B., & Strosznajder, R. P. (2016) · Neurochemical Research · doi:10.1007/s11064-015-1776-x · Cited by 131
NLRP3 inflammasome signalling in Alzheimer's disease
McManus, R. M., & Latz, E. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109941 · Cited by 144
Annese, A., Manzari, C., Lionetti, C., Picardi, E., Horner, D. S., Chiara, M., Caratozzolo, M. F., Tullo, A., Fosso, B., Pesole, G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22701-2 · Cited by 128
Morris, A. W. J., Carare, R. O., Schreiber, S., & Hawkes, C. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00251 · Cited by 122
Brain Iron Homeostasis: A Focus on Microglial Iron
Nnah, I. C., & Wessling-Resnick, M. (2018) · Pharmaceuticals · doi:10.3390/ph11040129 · Cited by 126
Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer’s Disease
Jiang, L., Dong, H., Cao, H., Ji, X., Luan, S., & Liu, J. (2019) · Medical Science Monitor · doi:10.12659/msm.914027 · Cited by 127
Griciuc, A., Federico, A. N., Natasan, J., Forte, A. M., McGinty, D., Nguyen, H., Volak, A., LeRoy, S., Gandhi, S., Lerner, E. P., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa179 · Cited by 121
Self-citationDeveloping Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
Self-citationRole of BACE1 in Alzheimer’s synaptic function
Das, B., & Yan, R. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0093-5 · Cited by 121
Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker
Duran-Frigola, M., Pauls, E., Guitart-Pla, O., Bertoni, M., Alcalde, V., Amat, D., Juan-Blanco, T., & Aloy, P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0502-7 · Cited by 126
Epigenomics of Alzheimer's disease
Bennett, D. A., Yu, L., Yang, J., Srivastava, G. P., Aubin, C., & De Jager, P. L. (2015) · Translational Research · doi:10.1016/j.trsl.2014.05.006 · Cited by 123
Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., & Bronfman, F. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r115.053330 · Cited by 117
Alzheimer’s Disorder: Epigenetic Connection and Associated Risk Factors
Sharma, V., Mehta, V., & Singh, T. G. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200128125641 · Cited by 134
The role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 119
Metadata
- Authors
- Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tanzi, R. E.
- ORCID
- Tanzi, R. E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-07-25
- Volume
- 2
- Issue
- 10
- Pages
- a006296-a006296
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W4233829850
- Cited by
- 727
- References
- 55
- Citations by year
- 2026: 40 · 2025: 55 · 2024: 58 · 2023: 70 · 2022: 54 · 2021: 49 · 2020: 54 · 2019: 40 · 2018: 42 · 2017: 55 · 2016: 60 · 2015: 52 · 2014: 61 · 2013: 32 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genetic susceptibility, familial Alzheimer's disease, APP mutations, presenilin 1, presenilin 2, apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, twin and family studies, genome-wide association study, candidate genes, heritability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.